We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Allakos Inc (ALLK) USD0.001

Sell:$3.21 Buy:$3.22 Change: $0.19 (6.29%)
NASDAQ:1.75%
Market closed |  Prices as at close on 5 July 2022 | Switch to live prices |
Sell:$3.21
Buy:$3.22
Change: $0.19 (6.29%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 5 July 2022 | Switch to live prices |
Sell:$3.21
Buy:$3.22
Change: $0.19 (6.29%)
Market closed |  Prices as at close on 5 July 2022 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Allakos Inc. is a clinical stage biotechnology company. The Company is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. It is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It also developed a formulation of lirentelimab for subcutaneous (SC) administration. The Company is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

Contact details

Address:
825 INDUSTRIAL ROAD, SUITE 500
SAN CARLOS
94070
United States
Telephone:
+1 (650) 5975002
Website:
www.allakos.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ALLK
ISIN:
US01671P1003
Market cap:
$165.43 million
Shares in issue:
54.78 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Adam Tomasi
    President, Chief Operating Officer
  • Robert Alexander
    Chief Executive Officer, Director
  • Baird Radford
    Chief Financial Officer
  • Meg Fitzgerald
    Senior Vice President, Chief Compliance Officer, General Counsel, Company Secretary
  • Craig Paterson
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.